USANA HEALTH SCIENCES INC Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD from Q4 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Usana Health Sciences Inc quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and growth rate from Q4 2015 to Q3 2024.
  • Usana Health Sciences Inc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending September 28, 2024 was $368M, a 18.7% increase year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $368M +$57.9M +18.7% Sep 28, 2024 10-Q 2024-11-05
Q2 2024 $335M +$32.2M +10.6% Jun 29, 2024 10-Q 2024-08-06
Q1 2024 $331M +$32.7M +11% Mar 30, 2024 10-Q 2024-05-07
Q4 2023 $333M +$41.9M +14.4% Dec 30, 2023 10-K 2024-02-27
Q3 2023 $310M +$59.5M +23.7% Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $303M +$68.9M +29.4% Jul 1, 2023 10-Q 2024-08-06
Q1 2023 $298M +$56.8M +23.5% Apr 1, 2023 10-Q 2024-05-07
Q4 2022 $291M +$47.7M +19.6% Dec 31, 2022 10-K 2024-02-27
Q3 2022 $250M -$1.53M -0.61% Oct 1, 2022 10-Q 2023-11-07
Q2 2022 $234M -$34.5M -12.9% Jul 2, 2022 10-Q 2023-08-08
Q1 2022 $242M -$18.5M -7.11% Apr 2, 2022 10-Q 2023-05-09
Q4 2021 $244M -$72.3M -22.9% Jan 1, 2022 10-K 2024-02-27
Q3 2021 $252M -$29.5M -10.5% Oct 2, 2021 10-Q 2022-11-08
Q2 2021 $269M +$38.4M +16.7% Jul 3, 2021 10-Q 2022-08-09
Q1 2021 $260M +$63.2M +32.1% Apr 3, 2021 10-Q 2022-05-11
Q4 2020 $316M +$78.2M +32.9% Jan 2, 2021 10-K 2023-02-28
Q3 2020 $281M +$95.8M +51.6% Sep 26, 2020 10-Q 2021-11-10
Q2 2020 $230M -$4.07M -1.74% Jun 27, 2020 10-Q 2021-08-11
Q1 2020 $197M -$31.1M -13.6% Mar 28, 2020 10-Q 2021-05-11
Q4 2019 $238M +$20.5M +9.42% Dec 28, 2019 10-K 2022-03-01
Q3 2019 $186M -$57.2M -23.6% Sep 28, 2019 10-Q 2020-11-03
Q2 2019 $234M -$25.2M -9.71% Jun 29, 2019 10-Q 2020-08-04
Q1 2019 $228M -$41.7M -15.5% Mar 30, 2019 10-Q 2020-05-05
Q4 2018 $217M -$33.3M -13.3% Dec 29, 2018 10-K 2021-03-02
Q3 2018 $243M +$47.7M +24.5% Sep 29, 2018 10-Q 2019-11-05
Q2 2018 $259M +$26.8M +11.5% Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $270M +$90.2M +50.2% Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $251M +$71.6M +40% Dec 30, 2017 10-K 2020-02-25
Q3 2017 $195M Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $233M Jul 1, 2017 10-Q 2018-08-08
Q1 2017 $180M Apr 1, 2017 10-Q 2018-05-09
Q4 2016 $179M +$32.2M +22% Dec 31, 2016 10-K 2020-02-25
Q4 2015 $147M Jan 2, 2016 10-K 2019-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.